Tag: study
Ministry refuses launch of research on proposed subsea cable : Cayman...
Existing Maya-1 undersea cable
(CNS): The planning and infrastructure ministry has released some documents relating to the proposed new undersea communications cable and the...
‘Positive results from PK study with cobitolimod’ selected as one of...
STOCKHOLM, Aug. 22, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the positive results from the pharmacokinetic (PK) study with...
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea...
Rochester, NY August 18, 2023 --(PR.com)-- The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world...
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in...
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2...
Global Times: Beautiful China as a case study for developing nations...
BEIJING, July 25, 2023 /PRNewswire/ -- At a national conference on ecological and environmental protection held from Monday to Tuesday, Chinese President Xi...
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in...
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint
The ENB-003 in combination...
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational...
- Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran's Promising Impact on Key Markers of Liver Disease
- AATD-LD is a Rare...
New ENRICH-PLUS Study Builds on World’s First Positive Clinical Trial for...
NICO awards University of Maryland $200,000 for first-of-its-kind study combining MIPS with neuroprotectant for basal ganglia ICHINDIANAPOLIS, June 22, 2023 /PRNewswire/ -- Just two...
Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First…...
Modifying patients' T-cells with mRNA to express a chimeric antigen receptor (rCAR-T therapy) a novel approach to treat myasthenia gravis and other autoimmune...
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring...
MELBOURNE, Australia, June 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today announces that the first patient has been dosed in...